KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inovio Pharmaceuticals (INO) Common Equity (2016 - 2025)

Inovio Pharmaceuticals (INO) has disclosed Common Equity for 16 consecutive years, with $24.1 million as the latest value for Q4 2025.

  • Quarterly Common Equity fell 64.82% to $24.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $24.1 million through Dec 2025, down 64.82% year-over-year, with the annual reading at $24.1 million for FY2025, 64.82% down from the prior year.
  • Common Equity hit $24.1 million in Q4 2025 for Inovio Pharmaceuticals, up from -$7.7 million in the prior quarter.
  • In the past five years, Common Equity ranged from a high of $581.6 million in Q1 2021 to a low of -$7.7 million in Q3 2025.
  • Historically, Common Equity has averaged $206.9 million across 5 years, with a median of $153.8 million in 2023.
  • Biggest five-year swings in Common Equity: skyrocketed 209.61% in 2021 and later crashed 110.5% in 2025.
  • Year by year, Common Equity stood at $399.7 million in 2021, then plummeted by 44.36% to $222.4 million in 2022, then tumbled by 47.23% to $117.3 million in 2023, then tumbled by 41.62% to $68.5 million in 2024, then crashed by 64.82% to $24.1 million in 2025.
  • Business Quant data shows Common Equity for INO at $24.1 million in Q4 2025, -$7.7 million in Q3 2025, and $28.5 million in Q2 2025.